Valeo Financial Advisors LLC Grows Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Valeo Financial Advisors LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 40.0% in the 3rd quarter, HoldingsChannel reports. The fund owned 1,547 shares of the biopharmaceutical company’s stock after acquiring an additional 442 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $1,626,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Sachetta LLC raised its position in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares in the last quarter. Stephens Consulting LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter worth $26,000. West Paces Advisors Inc. raised its position in Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares in the last quarter. Crewe Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the first quarter worth $28,000. Finally, Lynx Investment Advisory purchased a new position in Regeneron Pharmaceuticals in the second quarter worth $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on REGN shares. StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. Royal Bank of Canada upped their target price on Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the company an “outperform” rating in a report on Friday, October 4th. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. TD Cowen upped their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Finally, JPMorgan Chase & Co. upped their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. One research analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,119.00.

Regeneron Pharmaceuticals Stock Up 1.7 %

Shares of NASDAQ:REGN opened at $1,015.67 on Friday. The stock’s 50-day moving average price is $1,118.02 and its two-hundred day moving average price is $1,038.90. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $769.19 and a 12-month high of $1,211.20. The firm has a market cap of $111.91 billion, a price-to-earnings ratio of 30.01, a PEG ratio of 3.45 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same period last year, the company earned $8.79 EPS. The firm’s quarterly revenue was up 12.3% on a year-over-year basis. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.82 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now directly owns 4,204 shares in the company, valued at $4,498,280. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.